International Myopia Institute Welcomes Oculus To Join In Tackling Myopia Awareness

July 21, 2021

Sydney, Australia, July 21, 2021 – The International Myopia Institute (IMI) is pleased to announce that German ophthalmic medical device manufacturer, OCULUS, has announced their support of IMI activities to advance the research and awareness of myopia to prevent future vision impairment and blindness.

“We are thrilled to have OCULUS join in our mission to advance research, patient management and education in myopia. Open collaboration and sharing of knowledge globally with eye care practitioners (ECPs) are critical to prevent future myopia-related vision impairment and blindness,” said IMI Executive Director, Dr Monica Jong. “We will continue to bring the latest, evidence-based information directly to all ECPs across the world which would not be possible without our industry supporters.”

OCULUS’s sponsorship of the International Myopia Institute (IMI) comes at an exciting time in myopia research. The IMI recently published Volume two of the 2021 white papers and yearly digest in a special issue of the peer-reviewed Investigative Ophthalmology and Visual Science (IOVS) and is now releasing the IMI 2021 clinical summaries.

German ophthalmic medical device manufacturer, OCULUS, has joined IMI as a sponsor.

Christian Kirchhübel, CEO of OCULUS announces: “We are delighted about the cooperation. Our mission at OCULUS is to support eye care professionals around the world with cutting-edge, high-tech development. We love saving and improving vision and are known for our innovative and reliable measurement solutions.”

“There remains much to do in terms of growing myopia awareness and improving both eye care practitioner and the general public’s knowledge of the need and ability to slow myopia progression clinically,” added IMI Chair, Professor Serge Resnikoff. “We are looking forward to continuing to work with OCULUS and all our sponsors in making evidence-based knowledge on myopia treatment and prevention freely available.”

Access all the latest IMI white papers and clinical summaries in up to twelve international languages at myopiainstitute.org/imi-white-papers/.

ENDS

ABOUT THE INTERNATIONAL MYOPIA INSTITUTE
The International Myopia Institute arose at the WHO-BHVI meeting on myopia and high myopia in 2015, due to the need to address the increasing levels of myopia and high myopia worldwide that can lead to potentially sight threatening complications for an individual, and the massive global burden associated with lost productivity.

The IMI is a global group of experts who have come together to discuss, debate and make available the latest evidence-based recommendations in classifications, patient management, and research, in the form of the IMI white papers.

Our mission is to advance research, patient management and education in myopia to prevent future vision impairment and blindness associated with increasing myopia.  We aim to do this by bringing together, scientists, clinicians, policy makers, government and educators into the field of myopia to stimulate collaboration and sharing of knowledge.

Founded by Brien Holden Vision Institute (BHVI).
Supported by Zeiss, Essilor, CooperVision, Alcon and OCULUS.

ABOUT OCULUS
Since 1895, OCULUS has been a partner for eye care professionals around the world. With about 450 employees, OCULUS consistently develops and produces an extensive range of over 150 products at their headquarters in Wetzlar, Germany. All of OCULUS’s products are manufactured exclusively in Germany, with over 60 % of production distributed worldwide.

IMI_logo
© THE INTERNATIONAL MYOPIA INSTITUTE 2021
Advancing myopia research and education, to prevent future blindness
No citation data has been entered for this IMI Whitepaper